Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN BRAZIL

April 16, 2021

View Press Release Corporate presentation Contact us
Previous